[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"benzodiazepine-withdrawal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:benzodiazepine-withdrawal":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100550382","brief-motivational-intervention-bmi-on-the-deprescription-of-benzodiazepines-and-related-substances-in-adult-chronic-drug-users-100550382",false,"NCT06446349","Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users","Impact of Identification and Brief Motivational Intervention in Dispensing Pharmacies (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users","BENZ_HALTE","Inclusion Criteria:\n\n* Continuous treatment (at least once daily) with BZD\u002FZ for at least 6 months, after verification of 6 months' supply.\n* Signed informed consent\n* Patient able to understand the survey and complete a questionnaire in French.\n* Affiliation with the French social security system\n\nExclusion Criteria:\n\n* Concomitant treatment with:\n\n  * The following oral antipsychotics: risperidone, olanzapine, aripiprazole, quetiapine, clozapine, haloperidol, flupentixol, pimozide, chlorpromazine, sulpiride, zuclopenthixol, loxapine, cyamemazine (\\>100mg\u002FD), sulpiride (\\>150mg\u002FD),\n  * Injectable medium- and long-acting antipsychotics\n  * Thymoregulatory treatment with lithium\n  * Treatments for alcohol use disorders: baclofen, nalmefene, naltrexone, acamprosate, disulfiram\n  * Opiate substitution treatments: buprenorphine, methadone\n  * Anti-epileptic drugs\n* History of convulsions or epilepsy\n* History of gabaergic withdrawal accidents: delirium tremens, confusional syndrome requiring specialist treatment (hospitalisation, specialist consultation), epileptic seizures, etc.\n* Patients suffering from cancer\n* Persons referred to in articles L1121-5 to L1121-8 of the French Public Health Code (corresponding to all protected persons: pregnant women, women in childbirth, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons subject to a legal protection measure).","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","We hypothesise that a short-term intervention by dispensing pharmacists is feasible and relatively easy to implement, and that it could have an impact on the deprescribing of BZD\u002FZ in adult patients.\n\nTwo primary objectives will be evaluated in a sequential hierarchical manner, with two primary endpoints analysed one after the other, without alpha risk adjustment, but the second can only be analysed if the null hypothesis is rejected for the first:\n\n1. Evaluate the impact of brief motivational intervention (BMI) on reducing the daily dose of BZD\u002FZ prescribed at 6 months (superiority hypothesis) compared with the usual practice of dispensing BZD\u002FZ in pharmacies.\n2. Evaluate the impact of BMI on clinical worsening at 6 months (non-inferiority hypothesis) in comparison with the usual practice of dispensing BZD\u002FZ in pharmacies.",[27],"Benzodiazepine Withdrawal",[29,30],"substance use disorder","community pharmacy","RECRUITING","2026-09-29",{"date":34,"type":35},"2026-10-02","ACTUAL",{"date":37,"type":35},"2024-12-03",{"date":39,"type":21},"2027-04-03",{"name":41,"class":42},"University Hospital, Grenoble","OTHER",20,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100432543","can-connected-devices-increase-the-success-rate-of-benzodiazepine-withdrawals-in-the-elderly-100432543","NCT04912479","Can Connected Devices Increase the Success Rate of Benzodiazepine Withdrawals in the Elderly?","BENZO-E-STOP","Inclusion Criteria:\n\n* Unassisted mobility (1\u002F1 for the locomotion item on KATZ Activities of Daily Living scale)\n* Mini-Mental State Examination (MMSE) ≥ 20\n* With a daily consumption of benzodiazepine for more than 3 months\n* Smartphone and\u002For tablet with internet connection\n\nExclusion Criteria:\n\n* Patient under legal protection\n* Patient refuses to participate\n* Patient does not speak French","65 Years",{"count":53,"type":21},100,[24],"This is a prospective randomized open study, which aims to evaluate the benefit of a connected watch to help people aged 65 years and older to withdraw from BZD over a six-month period, compared with classical withdrawal (e.g without connected watch). The study will include 100 patients, 50 in the control group and 50 in the intervention group.\n\nParticipants will be identified during a 12-month period through either external geriatric consultations or during a brief hospitalisation.",[27],"2024-09-23",{"date":59,"type":35},"2024-09-25",{"date":61,"type":35},"2021-10-14",{"date":63,"type":21},"2026-02-01",{"name":65,"class":42},"University Hospital, Toulouse",1]